Search / Trial NCT06616558

A Study to Assess the Effectiveness of Sunscreen on Oil Control, Moisturization, and Skin Barrier Integrity in Adults With Oily Skin

Launched by JNTL CONSUMER HEALTH (BRASIL) LTDA · Sep 26, 2024

Apply for Trial

Trial Information

Current as of December 21, 2024

Completed

Keywords

ClinConnect Summary

The objectives of this study are:

To evaluate the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics:

* Instrumental measurements with the Sebumeter® SM 815 equipment to assess oiliness control;
* Clinical efficacy evaluation carried out by Expert Grader
* Perceived efficacy through perception questionnaires

To evaluate the efficacy of an investigational product in reducing oiliness, improving hydration, pores appearance and the integri...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Men and/or Women;
  • • 18 to 55 years old;
  • • Phototypes I to VI according to the Fitzpatrick classification;
  • • Subjects of any ethnicity according to Brazilian Institute of Geography and Statistics (IBGE) criteria
  • • Integral skin in the test areas;
  • • Subjects with oily skin, confirmed by instrumental measurements: (sebumetry value of at least 100μg/cm² in the frontal region (average of 3 measurements)).
  • • Subjects with face oil shine - confirmed by Dermatologist;
  • • Subjects with enlarged pores on the face - confirmed by a Dermatologist;
  • • Subjects with self-perceived combination/oily or very oily skin on the face;
  • • Subjects with a self-perceived oil shine on the face;
  • • Subjects with self-perceived enlarged pores on the face;
  • • Do not use cosmetic products (including usual soap) the night before the visit and do not wash your face after 10 p.m. the day before the visit;
  • • For male subjects: who agree to shave 48 hours before the visits;
  • • Generally, in good health based on medical history reported by the subject;
  • • Subjects able to read, write, speak, and understand Portuguese;
  • • Agreeing to adhere to the procedures and requirements of the study and attending the Site on the day(s) and time(s) set for the evaluations;
  • • Subjects who signed the terms Informed Consent Document (ICD) and Informed Consent Image Disclosure (ICID);
  • • Intends to complete the study and is willing and able to follow all the study instructions.
  • Exclusion Criteria:
  • • Has known allergies or adverse reactions to common topical skin care products including sunscreens;
  • • Presents a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer);
  • • Have primary/secondary lesions (e.g. scars, ulcers, vesicles) or tattoos in the test areas;
  • • Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication;
  • * Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
  • • Immunosuppressive or steroidal drugs within 2 months before Visit 1\*
  • • Non-steroidal anti-inflammatory drugs within 5 days before Visit 1\* (For Oxaprozin and Piroxicam consider 2 weeks before visit 1).
  • • Antihistamines within 2 weeks before Visit 1\* \*If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Study Physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "Concurrent/Concomitant Medication".
  • • Use of any other products capable of interfering with the study evaluations, at the discretion of the dermatologist;
  • • Subjects who have undergone invasive aesthetic or dermatological treatment in the test area within 2 months prior to the start of the study or during the study;
  • • Subjects who had used cosmetic products to treat oiliness/shine on the same area (face) within 14 days prior to the start of the study;
  • • Subjects who are using any medication to treat diseases of the face or eyes;
  • • Subjects who reported being pregnant, or planning to become pregnant during the study;
  • • Has a history of or a concurrent health condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study;
  • • Simultaneously taking part in another study;
  • • Being an employee/contractor or close relative of the Principal Investigator, Study Site, or Sponsor;
  • • Excessive hair in the assessment area that could interfere with instrumental measurements.

Trial Officials

Gabrielli Brianezi, PhD

Principal Investigator

Johnson & Johnson Consumer Inc. (J&JCI)

About Jntl Consumer Health (Brasil) Ltda

JNTL Consumer Health (Brasil) Ltda. is a prominent entity in the consumer health sector, dedicated to enhancing the well-being of individuals through innovative healthcare solutions. With a strong commitment to research and development, the company focuses on delivering high-quality products that meet the evolving needs of consumers. JNTL leverages its expertise in clinical trials to ensure safety and efficacy, positioning itself as a trusted sponsor in the healthcare landscape. Through strategic collaborations and a consumer-centric approach, JNTL aims to contribute significantly to the advancement of health outcomes in Brazil and beyond.

Locations

Campinas, São Paulo, Brazil

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0